Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.
You may also be interested in...
After Pulling IPO, Anacor Raises $50 Million In Equity Financing
Boron compound-focused biotech says proceeds should fund two years of operations.
After Pulling IPO, Anacor Raises $50 Million In Equity Financing
Boron compound-focused biotech says proceeds should fund two years of operations.
GlaxoSmithKline Invests In Anacor’s Boron-Based Anti-Infectives
Discovery and development deal gives Anacor $12 million upfront, with potential to earn more than $2 billion in milestones for eight possible products.